S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$47.55
-2.43 (-4.86 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.33
Now: $47.55
$49.64
50-Day Range
$48.19
MA: $51.39
$54.26
52-Week Range
$14.16
Now: $47.55
$55.22
Volume220,655 shs
Average Volume212,796 shs
Market Capitalization$1.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics logo

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

241st out of 1,558 stocks

Pharmaceutical Preparations Industry

123rd out of 638 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505
Employees65

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Market Cap$1.93 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$47.55
-2.43 (-4.86 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock price been impacted by Coronavirus?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, YMAB stock has increased by 106.9% and is now trading at $47.55.
View which stocks have been most impacted by COVID-19
.

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Y-mAbs Therapeutics
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its earnings results on Thursday, November, 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.02.
View Y-mAbs Therapeutics' earnings history
.

What price target have analysts set for YMAB?

8 equities research analysts have issued 12-month price objectives for Y-mAbs Therapeutics' shares. Their forecasts range from $45.00 to $71.00. On average, they anticipate Y-mAbs Therapeutics' share price to reach $58.33 in the next year. This suggests a possible upside of 22.7% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 50, Pay $766.75k)
  • Dr. Claus Juan Møller San Pedro M.D., Ph.D., CEO & Director (Age 58, Pay $967.5k)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 48, Pay $608.35k)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 46)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 69)
  • Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 41)
  • Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $47.55.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.93 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 65 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.